Use, efficacy and safety of prasugrel in patients with ST segment elevation myocardial infarction scheduled for primary percutaneous coronary intervention in clinical practice. Results of the prospective ATACS-registry

International Journal of Cardiology

Volumn 184, Issue 1, 2015, Pages 122-127

  Zeymer, Uwe ^a,b   Hochadel, Matthias ^b   Lauer, Bernward ^c   Kaul, Norbert ^d   Wöhrle, Jochen ^e   Andresen, Dietrich ^f   Schwimmbeck, Peter ^g   Solzbach, Ulrich ^h   Thiele, Holger ⁱ   Gitt, Anselm ^a,b   Diller, Frank ^b   Zahn, Ralf ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b Institut fuer Herzinfarktforschung   (Germany)

^c Zentrallinik Bad Berka   (Germany)

^d Stiftungsklinikum Mittelrhein   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f VIVANTES KLINIKUM AM URBAN   (Germany)

^g KLINIKUM LEVERKUSEN   (Germany)

^h Ostalb Klinikum Aalen   (Germany)

ⁱ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Antiplatelet therapy; Clopidogrel; Percutaneous coronary intervention; Prasugrel; ST elevation myocardial infarction

Indexed keywords

CLOPIDOGREL; PRASUGREL; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; DISEASE REGISTRY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; HEART REINFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOSIS; ACUTE CORONARY SYNDROME; CHEMICALLY INDUCED; CONTROLLED STUDY; HEMORRHAGE; HOSPITAL MANAGEMENT; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIAL; REGISTER; TREATMENT OUTCOME; TRENDS; VERY ELDERLY;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; APPOINTMENTS AND SCHEDULES; FEMALE; HEMORRHAGE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PROSPECTIVE STUDIES; REGISTRIES; TREATMENT OUTCOME;

EID: 84933533208     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.01.047     Document Type: Article

References (20)

1. P.G. Steg, S.K. James, D. Atar, et al., ESC guidelines for themanagement of acute myocardial infarction in patients presenting with ST-segment elevation, Eur. Heart J. 33 (2012) 2569-2619.
2. P.T. O'Gara, F.G. Kushner, D.D. Ascheim, et al., 2013 ACCF/AHA guidelines for the management of ST-elevation myocardial infarction, Circulation 127 (2013) e362-e425.
3. U. Zeymer, A. Gitt, C. Jünger, et al., Clopidogrel in addition to aspirin reduces inhospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial infraction, Thromb. Haemost. 99 (2008) 155-160.
4. COMMIT collobarative group, Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial, Lancet 366 (2005) 1607-1621.
5. U. Zeymer, A.K. Gitt, C. Jünger, et al., Effect of clopidogrel on 1-yearmortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice, Eur. Heart J. 27 (2006) 2661-2666.
6. G. Montalescot, G. Sideris, C. Meulemann, et al., A randomized comparison of high clopidogrel loading doses in patients with non-ST segment elevation acute coronary syndromes. The ALBION trial, J. Am. Coll. Cardiol. 48 (2006) 931-938.
7. J.A. Jakubowski, K.J. Winters, H. Naganuma, L. Wallentin, Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile, Cardiovasc. Drug Rev. 25 (2007) 357-374.
8. S.D. Wiviott, E. Braunwald, C.H. McCabe, et al., Prasugrel versus clopidogrel in patients with acute coronary syndromes, N. Engl. J. Med. 357 (2007) 2001-2015.
9. G. Montalescot, S.D. Wiviott, E. Braunwald, et al., Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for STelevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial, Lancet 373 (2009) 723-731.
10. H. Rittger, M. Hochadel, S. Behrens, et al., Age-related differences in diagnosis, treatment and outcome of acute coronary syndromes: results from the German ALKK registry, EuroIntervention 7 (2012) 1197-1205.
11. U. Zeymer, R. Zahn, M. Hochadel, et al., Indikationen und Komplikationen bei Herzkatheterdiagnostik und percutaner coronarer Intervention im Jahr 2003. Ergebnisse des Qualitätssicherungs-Registers der Arbeitsgemeinschaft Leitende kardiologische Krankenhausärzte (ALLK), Z. Kardiol. 94 (2005) 392-398.
12. The GUSTO investigators, An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction, N. Engl. J. Med. 329 (1993) 673-682.
13. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000984/WC500021971.pdf (accessed on March 12th 2014).
14. S.D. Wiviott, E. Braunwald, D.J. Angiolillo, et al., Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38, Circulation 118 (16) (2008) 1626-1636.
15. S.D. Wiviott, N. Desai, S.A. Murphy, et al., Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies, Am. J. Cardiol. 108 (2011) 905-911.
16. A.C. Salisbury, K. Wang, D.J. Cohen, et al., Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel, Circ. Cardiovasc. Qual. Outcomes 6 (2013) 27-34.
17. P. Damman, C. Varenhorst, S. Koul, et al., Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]), Am. J. Cardiol. 113 (2014) 64-69.
18. A. Koshy, K. Balasubramaniam, A. Noman, et al., Antiplatelet therapy in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a retrospective observational study of prasugrel and clopidogrel, Cardiovasc. Ther. 32 (2014) 1-6.
19. R. Beigel, P. Fefer, N. Rosenberg, et al., Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction, Am. J. Cardiol. 112 (2013) 1551-1556.
20. Y. Li, B.C. Tai, W. Sia, et al., Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention, J. Thromb. Thrombolysis 34 (2012) 499-505.